Patients undergoing Nuclear Medicine procedures, whether diagnostic or therapeutic, become radioactive sources for a period of time until the radioactive substance they incorporate is completely eliminated from their organisms. As a consequence, radioactive patients may expose other individuals and the environment to ionizing radiation. In order to reduce these exposures, radioprotective care with these patients is usually required. However, the small amount of radioactive material administered in diagnostic procedures leads to the question of the real need for such care and, even if this need is proven, it is still necessary to establish the period of its validity.There are no scientific studies in the literature to establish such care and its adequacy according to the clinical needs of each patient. Answers to these questions are linked to the true exposure potential these patients offer to other individuals, as well as the radiological risks arising from these exposures and radiation doses. Thus, this study primarily aims to evaluate these exposure potentials based on the study of patient-received radiopharmaceutical retention and excretion bikinetics, as well as to evaluate the radioprotective care to be implemented in diagnostic Nuclear Medicine either to reduce or control family exposures. and other individuals of the Society who may be exposed to these patients.